标题
Treatment of HER2-positive breast cancer: current status and future perspectives
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 9, Issue 1, Pages 16-32
出版商
Springer Nature
发表日期
2011-11-29
DOI
10.1038/nrclinonc.2011.177
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Abstract 82: A comprehensive characterization of cholecalciferol supplementation induced changes in the vitamin D3metabolic pathway in metastatic colorectal cancer patients
- (2011) Josephia R. F Muindi et al. CANCER RESEARCH
- Abstract 81: Differential metabolic and viability responses of the A549 and MRC-5 cell lines upon exposure to selective organic inhibitors of glycolysis
- (2011) Ibrahim O. Farah et al. CANCER RESEARCH
- Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere'):
- (2011) L Gianni et al. CANCER RESEARCH
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
- (2011) Wenjin Yin et al. PLoS One
- Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2
- (2011) Rodrigo Dienstmann et al. Recent Patents on Anti-Cancer Drug Discovery
- Breast cancer, advanced
- (2010) ANNALS OF ONCOLOGY
- PI3K kinase and scaffold functions in heart
- (2010) Federico Damilano et al. Annals of the New York Academy of Sciences
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer
- (2010) Helena R. Chang CANCER
- A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
- (2010) Srikumar M. Raja et al. CANCER BIOLOGY & THERAPY
- Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
- (2010) Katri Köninki et al. CANCER LETTERS
- Transcriptional and Post-Translational Upregulation of HER3 (ErbB3) Counteracts Antitumor Effect of HER2 Tyrosine Kinase Inhibitors.
- (2010) J. Garrett et al. CANCER RESEARCH
- Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy.
- (2010) K. Blackwell et al. CANCER RESEARCH
- Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.
- (2010) D. Yardley et al. CANCER RESEARCH
- Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
- (2010) Teemu T. Junttila et al. CANCER RESEARCH
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- Integrating Bevacizumab Into the Treatment of Patients With Early-Stage Breast Cancer: Focus on Cardiac Safety
- (2010) Denise A. Yardley Clinical Breast Cancer
- Does Lapatinib Work against HER2-negative Breast Cancers?
- (2010) I. A. Mayer et al. CLINICAL CANCER RESEARCH
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
- (2010) M. R. Campbell et al. CLINICAL CANCER RESEARCH
- Trastuzumab
- (2010) Karly P. Garnock-Jones et al. DRUGS
- Figitumumab (CP-751,871) for cancer therapy
- (2010) Antonio Gualberto EXPERT OPINION ON BIOLOGICAL THERAPY
- Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
- (2010) Norma O’Donovan et al. INVESTIGATIONAL NEW DRUGS
- First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors
- (2010) Ramesh K. Ramanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Management of small HER2-positive breast cancers
- (2010) Susana Banerjee et al. LANCET ONCOLOGY
- Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
- (2010) Richard S. Finn et al. LIVER INTERNATIONAL
- Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA
- (2010) W. Xia et al. MOLECULAR CANCER THERAPEUTICS
- Treatment Beyond Progression: Is It Moving from Belief to Evidence?
- (2010) R. Yerushalmi et al. ONCOLOGIST
- Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
- (2010) L. S. Schwartzberg et al. ONCOLOGIST
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
- (2009) M. D. Green et al. ANNALS OF ONCOLOGY
- North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
- (2009) E. A. Perez et al. ANNALS OF ONCOLOGY
- Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
- (2009) K. L. Blackwell et al. ANNALS OF ONCOLOGY
- Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
- (2009) C. Sessa et al. ANNALS OF ONCOLOGY
- Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells
- (2009) Amelia D’Alessio et al. BREAST CANCER RESEARCH AND TREATMENT
- Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
- (2009) E. L. Mayer et al. BREAST CANCER RESEARCH AND TREATMENT
- The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
- (2009) C Horlock et al. BRITISH JOURNAL OF CANCER
- Adjuvant targeted therapy in early breast cancer
- (2009) John Mackey et al. CANCER
- Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients
- (2009) Mark G. Carmichael et al. CANCER
- PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough
- (2009) Nancy E. Hynes et al. CANCER CELL
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions
- (2009) Alberto Ocaña et al. CANCER TREATMENT REVIEWS
- Trastuzumab versus lapatinib: The cardiac side of the story
- (2009) Hamdy Azim et al. CANCER TREATMENT REVIEWS
- Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
- (2009) Denise A. Yardley et al. Clinical Breast Cancer
- A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
- (2009) C. M. Hartford et al. CLINICAL CANCER RESEARCH
- Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
- (2009) E. Yao et al. CLINICAL CANCER RESEARCH
- Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent
- (2009) Britt Erika Hanson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
- (2009) Charles Erlichman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cixutumumab
- (2009) Kevin P McKian et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study
- (2009) Lars M. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Progress in Defining and Treating High-Risk Neuroblastoma: Lessons From the Bench and Bedside
- (2009) Samuel L. Volchenboum et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
- (2009) Lilyana Angelov et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
- (2009) Marc Spielmann et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
- (2009) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
- (2009) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer
- (2009) Andrew M. Wardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial
- (2009) Ritesh Patil et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
- (2009) Edith A. Perez et al. MAYO CLINIC PROCEEDINGS
- BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
- (2009) K. Lundgren et al. MOLECULAR CANCER THERAPEUTICS
- Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
- (2009) M. Dokmanovic et al. MOLECULAR CANCER THERAPEUTICS
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
- (2009) Evandro de Azambuja et al. Targeted Oncology
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence
- (2008) Jarrod P. Holmes et al. CANCER
- The E75 HER2/neu peptide vaccine
- (2008) Elizabeth A. Mittendorf et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells
- (2008) Panagiotis Karagiannis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial)
- (2008) Valentina Guarneri et al. Clinical Breast Cancer
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
- (2008) C. L. Arteaga et al. CLINICAL CANCER RESEARCH
- Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2008) G. E. Peoples et al. CLINICAL CANCER RESEARCH
- Ertumaxomab: a trifunctional antibody for breast cancer treatment
- (2008) Philipp Kiewe et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Jumping higher: is it still possible? The ALTTO trial challenge
- (2008) Gianluca Tomasello et al. Expert Review of Anticancer Therapy
- Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
- (2008) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrent Priapism Related to Oxaliplatin Infusion
- (2008) Antoine Adenis et al. JOURNAL OF CLINICAL ONCOLOGY
- Including Persons With HIV Infection in Cancer Clinical Trials
- (2008) Govind C. Persad et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
- (2008) Stephen Chia et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now